Evolent Lifts 2026 Adjusted EBITDA Outlook to $130M–$135M
EVH has more than doubled off its 52-week low of $2.095.
Summary
Evolent raised its 2026 Adjusted EBITDA guidance to $130M–$135M while keeping revenue guidance at $2.6B–$2.7B. The EBITDA bump is the only upgrade in the release — revenue is unchanged, so the improvement points to better margins rather than faster top-line growth. Capitalized expenditures are pegged at $26M–$28M for the year, and cash stood at $148.3M on Sept. 30. The company reported a third-quarter loss of 21 cents a share on revenue of $725.4M. This follows the Q2 10-Q filed Aug. 6, which showed revenue up 47% year-over-year to $652.5M on new Performance Suite contracts. For a company with a small market cap, a higher EBITDA range is meaningful to earnings estimates, though the release gives no prior EBITDA range for comparison.
At the time of this announcement, EVH was trading at $4.47 on NYSE in the Life Sciences sector, with a market capitalization of approximately $542.7M. The 52-week trading range was $2.10 to $6.89. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.